Poly Medicure Ltd
Poly Medicure Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #7 of 12 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
The short version
Poly Medicure expects overall consolidated revenue growth of around 20% or more for FY '27. For FY '26, operating profit is expected to be similar to previous year (~INR450 crores).
From Poly Medicure Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Poly Medicure expects overall consolidated revenue growth of around 20% or more for FY '27.
- Domestic business is projected to grow between 20% to 25%, driven by a stronger private market presence.
- International business growth is expected in the 12% to 15% range, including contributions from recent acquisitions.
- New acquisitions and subsidiaries, such as Plan1 Health (oncology business), are contributing significant growth (e.g., 30-35% year-on-year for Plan1 Health).
- The company aims to regain a 20% constant growth rate after a challenging year.
- Growth strategies include expanding clinical teams internationally to better penetrate 25-30 major markets.
2 more points from Poly Medicure Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Poly Medicure Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex of INR 234 crores done in the first 9 months of the current financial year.
- Funds deployed to set up new factories in Mitrol and Haridwar, as well as to expand capacity at existing plants.
- Additional land bought at YEIDA Medical Devices Park near Noida in Jewar for a new facility.
- New facility expected to be operational within 18 to 24 months after local approvals.
- Three new plants planned to be fully operational within the next 18 to 24 months.
- Continued investments support ambitious growth strategy including organic and inorganic expansion.
2 more points from Poly Medicure Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Poly Medicure Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Poly Medicure Ltd's call on order book
Create a free account to keep reading this call
Poly Medicure Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹535 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Poly Medicure's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- QMS Medical (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how
- Nureca Ltd (Q3 FY26)
Q3 FY26 revenue from operations: INR 540 million (27% YoY growth) . Key investor presentation takeaways from Nureca's Q3 FY26 investor presentation — and how it
- Tarsons Products (Q3 FY26)
Tarsons has undertaken a significant capex of INR 600 crores announced in 2021-22, with partial commercialization in 2026. Key concall takeaways from Tarsons…
- Laxmi Dental (Q3 FY26)
Scanner sales growth to continue, with digital penetration in India planned to increase from 79% to 90%, driving future expansion. Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Molbio DiagnostiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Poly Medicure Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Poly Medicure Ltd Q3 FY26 results?
Poly Medicure expects overall consolidated revenue growth of around 20% or more for FY '27. For FY '26, operating profit is expected to be similar to previous year (~INR450 crores).
What is Poly Medicure Ltd share price analysis?
Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹17,317 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure Ltd planning capital expenditure?
Capex of INR 234 crores done in the first 9 months of the current financial year.
Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.